This site uses cookies to store information on your computer. Learn more x

DSM ComfortCoat® hydrophilic coating utilized in new drug eluting stent delivery system from CID SpA

Berkeley CA, US, 14 Nov 2011 16:15 CET

Cre8™ Drug Eluting Stent utilizes DSM’s proprietary coating technology to help interventional cardiologists improve patient outcomes

DSM, a global leader in biomedical materials science, today announced the use of its ComfortCoat® hydrophilic coating on the delivery system of CID SpA’s new Cre8 Drug Eluting Stent (DES), CE marked the 16th of July 2011.

CID SpA chose ComfortCoat hydrophilic coating, a proprietary DSM product and technology, since it facilitates the treatment of more complex patient anatomies by enhancing the deliverability of its stent delivery systems during percutaneous coronary intervention procedures.

Recently released data has not only proven the unmatched effectiveness of Cre8 DES in patients with coronary artery disease, but showcases the potential for this type of drug eluting stent system to help physicians shorten the dual antiplatelet therapy period for their patients. Further, CID is leveraging the latest advanced delivery system technologies, particularly the ComfortCoat hydrophilic coating, in order to maximize acute device performances.

“The launch of Cre8 DES aligns with our mission of supporting interventional cardiologists and their patients with the development of innovative systems that positively impact patient outcomes, in terms of efficacy and safety, while also helping to reduce costs within the healthcare delivery system,” said Franco Vallana, president and CEO of CID SpA. “By collaborating with DSM, we are able to ensure interventional cardiologists receive the benefits of the world’s most advanced technologies within our drug eluting stent systems.”

“Our long-standing partnership with CID reaffirms our continued commitment to providing innovative material solutions for the cardiovascular market, which, ultimately, help to lower patient risk and improve procedural outcomes,” said John Marugg, Business Manager Coatings, DSM Biomedical. “As DSM’s materials portfolio continues to expand with novel coating materials, the successful launch of Cre8 DES is another strong testament to the value we provide medical device manufacturers across the globe.”

This announcement precedes the start of COMPAMED, where DSM will be exhibiting in Hall 8a at booth K28 from November 16-18, 2011 in Düsseldorf, Germany.